Autologous CD19/BCMA CAR-T cell therapy for myasthenia gravis: Advancing care for those with severe disease

Authors

• Henry J. Kaminski, Laboratory for Myasthenia Gravis, George Washington University, Washington, DC, USA; Department of Neurology and Rehabilitation Medicine, George Washington University, Washington, DC, USA. Electronic address: [email protected].
• Linda L. Kusner, Laboratory for Myasthenia Gravis, George Washington University, Washington, DC, USA; Department of Pharmacology and Physiology, George Washington University, Washington, DC, USA.

Document Type

Journal Article

Publication Date

4-10-2026

Journal

Med (New York, N.Y.)

Volume

7

Issue

4

DOI

10.1016/j.medj.2026.101036

Abstract

Ruan and colleagues report that dual-target CD19/BCMA CAR-T cell therapy produced marked clinical improvement in highly refractory myasthenia gravis, with steroid discontinuation and minimal toxicity. Beyond symptom control, deep immune profiling revealed sustained B-cell depletion, reduced autoantibodies, and systemic immune reprogramming toward a less inflammatory state.

APA Citation

Kaminski, Henry J. and Kusner, Linda L., "Autologous CD19/BCMA CAR-T cell therapy for myasthenia gravis: Advancing care for those with severe disease" (2026). GW Authored Works. Paper 9078.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/9078

Department

Neurology